Universität zu Köln

Yang, Soo-Ryum, Schultheis, Anne M., Yu, Helena, Mandelker, Diana, Ladanyi, Marc and Buettner, Reinhard (2022). Precision medicine in non-small cell lung cancer: Current applications and future directions. Semin. Cancer Biol., 84. S. 184 - 199. LONDON: ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD. ISSN 1096-3650

Full text not available from this repository.

Abstract

Advances in biomarkers, targeted therapies, and immuno-oncology have transformed the clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there are highly effective targeted therapies against EGFR, ALK, ROS1, BRAF, TRK, RET, and MET. In addition, investigational therapies for KRAS, NRG1, and HER2 have shown promising results and may become standard-of-care in the near future. In parallel, immune -checkpoint therapy has emerged as an indispensable treatment modality, especially for patients lacking actionable oncogenic drivers. While PD-L1 expression has shown modest predictive utility, biomarkers for immune-checkpoint inhibition in NSCLC have remained elusive and represent an area of active investigation. Given the growing importance of biomarkers, optimal utilization of small tissue biopsies and alternative geno-typing methods using circulating cell-free DNA have become increasingly integrated into clinical practice. In this review, we will summarize the current landscape and emerging trends in precision medicine for patients with advanced NSCLC with a special focus on predictive biomarker testing.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Yang, Soo-Ryum UNSPECIFIED UNSPECIFIED UNSPECIFIED Schultheis, Anne M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Yu, Helena UNSPECIFIED UNSPECIFIED UNSPECIFIED Mandelker, Diana UNSPECIFIED UNSPECIFIED UNSPECIFIED Ladanyi, Marc UNSPECIFIED UNSPECIFIED UNSPECIFIED Buettner, Reinhard UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-665769
DOI:	10.1016/j.semcancer.2020.07.009
Journal or Publication Title:	Semin. Cancer Biol.
Volume:	84
Page Range:	S. 184 - 199
Date:	2022
Publisher:	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
Place of Publication:	LONDON
ISSN:	1096-3650
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language MOLECULAR TESTING GUIDELINE; OF-AMERICAN-PATHOLOGISTS; EXON 14 MUTATIONS; MET AMPLIFICATION; OPEN-LABEL; ACQUIRED-RESISTANCE; KINASE INHIBITOR; EGFR MUTATIONS; AMG 510; KRAS(G12C) INHIBITOR Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/66576